Tumor-agnostic therapies represent a radical shift in oncology. They abandon the traditional way of treating tumors based on cancer type and, instead, provide personalized options based on the genetic mutations. Today’s podcast is the 1st part of a 2-part series dedicated to agnostic treatments in cancer. Join us as Dr. Joshua Drago of Memorial Sloan Kettering Cancer Center shares his experience in the agnostic approach to cancer care. In this episode he discusses agnostic research and points out the advantages as well as the treatment limitations of agnostic therapeutics.

Resources on Agnostics:

The Evolving Landscape of Tissue-Agnostic Therapies in Precision Oncology

TAPUR (Targeted Agent & Profiling Study): The TAPUR Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration (FDA)- approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Sarat Chandarlapaty Lab at Memorial Sloan Kettering Cancer Center

Meet the Guest of the Episode